AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12153596
Drug: Dexamethasone (Dex)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (Dex) 6.5 mg/m2
Trial: 12153596
Drug: Prednisolone (Pred)
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone (Pred) 40 mg/m2
Trial: 7628186
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg prednisone
Trial: 2699147
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of five markers (CEA, SCC, TPA, CA 50, ferritin)
Trial: 15293490
Drug: Balance training
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance training and vestibular rehabilitation in group sessions twice a week for six weeks
Trial: 11430325
Drug: Indomethacin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.1 mg/kg body weight)
Trial: 8504634
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (4 x 5 g of creatine plus 1 g of glucose/day)
Trial: 27779482
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of alprazolam orally one hour before the procedure
Trial: 25404102
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (200 µg daily for 8 weeks, then 200 µg on alternate days for 16 weeks)
Trial: 25404102
Drug: Saline nasal
RxNorm normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline nasal spray (control)
Trial: 20083626
Drug: Pulsed infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed infusions of levosimendan (6 h administration at 0.2 microg/kg/min every 2 weeks)
Trial: 20083626
Drug: Pulsed infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed infusions of levosimendan
Trial: 12151930
Drug: NOx.5 l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOx.5 l (oxygen-nitrous oxide, MFA after 10 min high fresh gas flow)
Trial: 12151930
Drug: Ox.5 l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ox.5 l (oxygen, MFA)
Trial: 12151930
Drug: Ox1 l
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ox1 l (oxygen, LFA)
Trial: 12151930
Drug: NOx1 l
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOx1 l (oxygen-nitrous oxide, LFA after 10 min high fresh gas flow)
Trial: 10417507
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion into the brachial artery at a rate of 2 ml/100 ml forearm min‐1
Trial: 2855478
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no saline infusion)
Trial: 7305608
Drug: Clonidine hydrochloride,
RxNorm normalized name: CloNIDine Hydrochloride, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine hydrochloride, peak mean dose of 16 micro g/kg/day, administered for 10 to 11 days
Trial: 30227423
Drug: H2‐O2 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2‐O2 (6 L per min, H2:O2 = 2: 1) for 15 min
Trial: 30227423
Drug: O2 (3
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: O2 (3 L per min) for 15 min
Trial: 24611442
Drug: Desvenlafaxine 10-100
RxNorm normalized name: desvenlafaxine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 10-100 mg/day (children) or 25-200 mg/day (adolescents) for 8 months
Trial: 22700995
Drug: Ganitumab (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganitumab (12 mg/kg every 2 weeks) combined with gemcitabine (1000 mg/m2 on days 1, 8, and 15 of each 28-day cycle)
Trial: 22700995
Drug: Conatumumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conatumumab (10 mg/kg every 2 weeks) combined with gemcitabine (1000 mg/m2 on days 1, 8, and 15 of each 28-day cycle)
Trial: 22700995
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with gemcitabine (1000 mg/m2 on days 1, 8, and 15 of each 28-day cycle)
Trial: 13129985
Drug: Azithromycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (600 mg/d for 3 days during week 1, then 600 mg/wk during weeks 2‐12; n = 3879)
Trial: 10373219
Drug: Control (heparin)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (heparin)
Trial: 12024138
Drug: Endoscopic epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoscopic epinephrine injection
Trial: 1983848
Drug: Heat probe
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heat probe treatment
Trial: 6836750
Drug: Adjuvant hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormone therapy (gestonorone caproate, 200 mg/week for 1 year)
Trial: 30470892
Drug: Myofascial release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial release treatment (MR)
Trial: 30470892
Drug: Placebo manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo manual lymphatic drainage treatment (PMLD)
Trial: 29744966
Drug: Self-Book© art
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-Book© art therapy
Trial: 22695903
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid 500 mg twice daily
Trial: 20577914
Drug: Lateral-to-medial laparoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral-to-medial laparoscopic right hemi-colectomy (Group L)
Trial: 17379431
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy (IFRT)
Trial: 17379431
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HD-CT) followed by IFRT
Trial: 15679751
Drug: Weekly telephone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly telephone monitoring and counseling combined with a support group in the first 4 weeks (TEL)
Trial: 15679751
Drug: Twice-weekly standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly standard group counseling (STND)
Trial: 15679751
Drug: Twice-weekly individualized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly individualized relapse prevention (RP)
Trial: 12162978
Drug: Rhys‐Davies exsanguinator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhys‐Davies exsanguinator supplemented by a 500 ml bag of intravenous fluid
Trial: 2361795
Drug: High-dose prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prednisolone (120 mg/day)
Trial: 2361795
Drug: Low-dose prednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prednisolone (60 mg/day)
Trial: 23547487
Drug: Manual toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrush (Oral-B Indicator 30 Compact Soft Toothbrush)
Trial: 21454149
Drug: 10% C‐β‐D‐xylopyranoside‐2‐hydroxy‐propane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% C‐β‐D‐xylopyranoside‐2‐hydroxy‐propane (C‐xyloside) cream
Trial: 17016596
Drug: CKLQ (Cobrotoxin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKLQ (Cobrotoxin, tramadol hydrochloride, ibuprofen)
Trial: 1418362
Drug: Velnacrine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velnacrine 300 mg/day
Trial: 1418362
Drug: Velnacrine 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velnacrine 225 mg/day
Trial: 31481453
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) for stage IIIC
Trial: 30368249
Drug: 0.1% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% CHX solution (control group)
Trial: 26920601
Drug: Evolocumab (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (140 mg subcutaneously every 2 weeks or 420 mg subcutaneously every month)
Trial: 26920601
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo injections
Trial: 23207160
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blockers (ARB) - candesartan
Trial: 23207160
Drug: Beta-blockers -
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers - metoprolol
Trial: 23207160
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ARB and beta-blockers
Trial: 17062657
Drug: Once-weekly strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly strength training (1 day/week)
Trial: 17062657
Drug: Twice-weekly strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly strength training (2 days/week)
Trial: 15799683
Drug: Efalizumab 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab 1.0 mg/kg, administered subcutaneously once weekly for 12 weeks
Trial: 10211014
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural administration of ropivacaine
Trial: 10211014
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine and patient‐controlled analgesia (PCA) with i.v. morphine
Trial: 25803245
Drug: Intra‐articular 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra‐articular 20 ml of 0.25% bupivacaine 20 minutes before the start of the operation (preemptive: PE)
Trial: 25803245
Drug: No intra‐articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intra‐articular injection (control group: CG)
Trial: 23769553
Drug: Estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol valerate and progesterone capsule (group B, n = 32)
Trial: 21920203
Drug: Tibial and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibial and common fibular nerve block using percutaneous nerve stimulator with 10 mL of levobupivacaine injected at each nerve site.
Trial: 18218084
Drug: 5-option decision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-option decision aid (FOBT, sigmoidoscopy, combination of FOBT and sigmoidoscopy, colonoscopy, barium enema)
Trial: 10981219
Drug: Di-Te-Ki-Pol vaccine
RxNorm normalized name: di-isopropylammonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Di-Te-Ki-Pol vaccine 'SSI'
Trial: 10981219
Drug: DT-IPV plus
RxNorm normalized name: DT, IPV adsorbed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DT-IPV plus wholecell pertussis vaccine
Trial: 29222892
Drug: Oral Nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Nutritional Supplements (Peptamen)
Trial: 22811009
Drug: Bortezomib plus
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib plus Bevacizumab (1.3 mg/m² on days 1, 4, 8, and 11 of each 21-day cycle; Bevacizumab 15 mg/kg on day 1 of each cycle)
Trial: 22811009
Drug: Bortezomib monotherapy
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib monotherapy (1.3 mg/m² on days 1, 4, 8, and 11 of each 21-day cycle)
Trial: 16539916
Drug: Salbutamol and
RxNorm normalized name: salbutamol and budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol and terbutaline doses delivered via MDI with spacer (half the child's weight)
Trial: 16539916
Drug: Salbutamol and
RxNorm normalized name: salbutamol and budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol and terbutaline doses delivered via MDI with spacer (one-third of the child's weight)
Trial: 12562445
Drug: Esomeprazole, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole, 20 mg once daily
Trial: 11908405
Drug: 5.3% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.3% hydrogen peroxide tooth-bleaching gel, used twice daily for 2 weeks
Trial: 11908405
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between peroxide gel and placebo
Trial: 8296377
Drug: Artemether (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether (5 days intramuscular regimen)
Trial: 3520308
Drug: Flunarizine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (up to 0.25 mg/kg/day)
Trial: 23430885
Drug: Counting gram
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Counting gram protein exchanges (1g=50‐mg Phenylalanine)
Trial: 23430885
Drug: Counting Phe
RxNorm normalized name: Phe
DrugBank: Phenylalanine (DB00120)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Counting Phe unit exchanges (1unit=15‐mg Phenylalanine)
Trial: 20098447
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of gestational diabetes mellitus
Trial: 14999111
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin (conjugated equine estrogens 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day)
Trial: 8983284
Drug: Ondansetron 5
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron 5 mg/m2
Trial: 8983284
Drug: Ondansetron 10
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron 10 mg/m2
Trial: 8983284
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment arms (5 mg/m2 and 10 mg/m2)
Trial: 1751459
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of gentamicin at the end of the cataract procedure (Group G)
Trial: 1751459
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of gentamicin and a cellulose wick drain (Group GW)
Trial: 7064901
Drug: Reference dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference dose of inorganic iron (3 mg)
Trial: 31087065
Drug: Medication reconciliation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reconciliation at discharge by a clinical pharmacist, a prescription check for formal flaws, interactions and missing therapy durations.
Trial: 28340157
Drug: Cervical lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical lateral glide (CLG) treatment
Trial: 28340157
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) - waiting list for treatment
Trial: 10920403
Drug: Sumatriptan 100
RxNorm normalized name: sumatriptan 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 100 mg plus naproxen sodium 550 mg
Trial: 10920403
Drug: Sumatriptan 100
RxNorm normalized name: sumatriptan 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 100 mg plus placebo
Trial: 8959522
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with lansoprazole (30 mg o.d.) for 8 weeks plus clarithromycin (200 mg b.i.d.) or amoxicillin (250 mg q.i.d.) for 2 weeks
Trial: 8959522
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with lansoprazole (30 mg o.d.) and ecabet sodium (1.0 g b.i.d.) for 8 weeks plus clarithromycin (200 mg b.i.d.) or amoxicillin (250 mg q.i.d.) for 2 weeks
Trial: 1413183
Drug: Venoruton (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venoruton (300 mg x 3)
Trial: 30208960
Drug: Junctional Emergency
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Junctional Emergency Treatment Tool (JETT)
Trial: 26671007
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OT), 24 IU
Trial: 17572521
Drug: Ethyl chloride
RxNorm normalized name: Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl chloride spray (EC)
Trial: 17572521
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic Ametop (TA)
Trial: 15661445
Drug: Intravenous dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dextromethorphan (DM) 0.5 mg/kg
Trial: 10567867
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of recombinant tissue plasminogen activator (rtPA) and intravenous heparinization (n = 23)
Trial: 10567867
Drug: early-phase hemodilution
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: early-phase hemodilution therapy (n = 22)
Trial: 10567867
Drug: late-phase hemodilution
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: late-phase hemodilution therapy (n = 13)
Trial: 8724107
Drug: Lp(a) ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a) ≥ 20 mg/dl
Trial: 8724107
Drug: Lp(a) <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a) < 20 mg/dl
Trial: 2035283
Drug: 10.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.5 g fish oil daily
Trial: 2035283
Drug: 5.25 g
RxNorm normalized name: LIDOCAINE 5.25 g in 100 g RECTAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.25 g fish oil daily
Trial: 6786855
Drug: Carbenoxolone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone (50 mg Biogastron duodenal three times daily)
Trial: 22075648
Drug: Osmotic-release oral
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osmotic-release oral system (OROS) methylphenidate
Trial: 19433778
Drug: ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril (5 mg/d) at bedtime
Trial: 19433778
Drug: ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril (5 mg/d) on awakening
Trial: 11222463
Drug: Etanercept 5
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 5 mg/m2
Trial: 11222463
Drug: Etanercept 12
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept 12 mg/m2
Trial: 7912097
Drug: Zidovudine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (1000 mg daily in two divided doses)
Trial: 22099891
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ibuprofen combined with 1000 mg acetaminophen
Trial: 7019840
Drug: Pancuronium bromide
RxNorm normalized name: Pancuronium Bromide
DrugBank: Pancuronium (DB01337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pancuronium bromide (administered for 12 hours)
Trial: 7019840
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no pancuronium bromide, administered for 12 hours)
Trial: 22905878
Drug: Perampanel (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel (up to 12 mg/day)
Trial: 10367725
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (300 mg x kg(‐1) body mass)
Trial: 2200896
Drug: Thiamylal 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamylal 4 mg.kg‐1
Trial: 29045769
Drug: Active drugs
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drugs (olanzapine, quetiapine, risperidone)
Trial: 26464455
Drug: Suvorexant (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant (40 mg) with alcohol (0.7 g/kg)
Trial: 26464455
Drug: Suvorexant (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant (40 mg) alone
Trial: 26464455
Drug: Alcohol (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.7 g/kg) alone
Trial: 23261493
Drug: N-acetylcysteine (1200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (1200mg NAC twice daily)
Trial: 21876071
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg/d
Trial: 21876071
Drug: Telmisartan 160
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan 160 mg/d
Trial: 18611293
Drug: Medication augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication augmentation